Clinical trials: RNA Profile
HIV Infections
Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic…
- Trial name
- COOL (NCT00643968)
- Testing
- EFV+TDF, EFV+3TC+TDF
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)
This study is being done to find out if participants with insulin resistance and hepatitis C virus genotype 1 (HCV GT1) infections who failed dual therapy with peginterferon alfa (PegIFN) + ribavirin (RBV) will benefit from the…
- Trial name
- NCT01770223
- Testing
- boceprevir, PegIFN-2b, RBV
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Clinical Pharmacology Study of AZD7295 in Healthy Subjects
The purpose of this study is to determine the pharmacokinetic profile of oral doses of AZD7295 capsules in healthy subjects, and also to assess the effects of food as well as safety and tolerability.
- Trial name
- NCT00906256
- Testing
- AZD7295
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Arrow Therapeutics
COVID-19
Post Authorization Safety Study Moderna COVID-19 Primary Vaccine
This study is Post Authorization Safety Study (PASS) Phase IV of Moderna COVID-19 Primary Vaccine
- Trial name
- NCT06006858
- Testing
- Moderna COVID-19 Vaccine
- Where
- 18 sites in Indonesia
- Volunteers
- 1,284 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
HIV Infections
A Study of L-735,524 in HIV-Positive Children and Adolescents
To evaluate the safety, tolerability, and plasma concentration profiles of indinavir sulfate ( MK-639; Crixivan ) in HIV-seropositive older children and adolescents.
- Trial name
- NCT00002351
- Testing
- Indinavir sulfate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Covid19
Retrospective Study of ImmunoFormulation for COVID-19
Multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated or not with IMUNO TF ® and a combination of nutraceuticals and who have tested positive in a COVID-19 diagnostic…
- Trial name
- NCT04666753
- Testing
- ImmunoFormulation
- Where
- 2 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fagron Iberica S.A.U.
Preeclampsia
Molecular Screening Method for Preeclampsia (PREMOM)
Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening…
- Trial name
- PREMOM (NCT04990141)
- Testing
- Peripheral blood collection in cases group, Peripheral blood collection in control group
- Where
- 15 sites in Spain
- Volunteers
- 9,586 people
- Sponsor
- iPremom
HIV Infections
Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1
This was a prospective, non-interventional, single-arm, multi-center study aimed at gathering real-world data on JULUCA use in routine clinical care in Germany, to supplement clinical trial data to further improve/optimize care…
- Trial name
- JUNGLE (NCT03518060)
- Testing
- JULUCA
- Where
- 23 sites in Germany
- Volunteers
- 209 people
- Sponsor
- ViiV Healthcare
HIV Infection, HIV
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
The purpose of this study is to compare the neuropsychiatric adverse event profiles of etravirine 400mg once daily versus efavirenz 600mg once daily, in combination with 2 N(t)RTIs, in approximately 150 treatment-naÃ-ve HIV-1…
- Conditions
- HIV Infection, HIV, Acquired Immunodeficiency Syndrome
- Trial name
- SENSE (NCT00903682)
- Testing
- etravirine (ETR, TMC125), efavirenz (EFV)
- Where
- 33 sites in Austria, Denmark and 9 more
- Volunteers
- 157 people
- Sponsor
- Janssen-Cilag International NV
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Primary Objective: To demonstrate that high-dose quadrivalent influenza vaccine (QIV-HD) induces an immune response that is superior to the responses induced by standard-dose quadrivalent influenza vaccine (QIV-SD) for all 4…
- Trial name
- NCT04024228
- Testing
- Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD), High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 1,539 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV-1 Infection
A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).
The purpose of this study is to determine the pharmacokinetic profile of TMC125 400mg with tenofovir DF/emtricitabine FDC (fixed dose combination) 300/200mg all dosed once daily with and without darunavir/ritonavir 800/100 mg…
- Trial name
- NCT00534352
- Testing
- TMC125; darunavir; ritonavir
- Volunteers
- 23 people
- Sponsor
- Tibotec, Inc
Hepatitis C
Antiviral Activity of AZD7295 in HCV Carriers
PK, safety study of AZD7295 in HCV carriers
- Trial name
- NCT00781976
- Testing
- AZD7295
- Where
- New Zealand
- Volunteers
- 31 people
- Sponsor
- Arrow Therapeutics
HIV Infections
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
- Trial name
- NCT06741397
- Testing
- CAB LA, New formulation of CAB LA
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Covid19
Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.
- Trial name
- NCT04632706
- Testing
- Ivermectin
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- MedinCell S.A
Respiratory Syncytial Virus Infections
A Study of TNM001 in Chinese Healthy Preterm and Term Infants
The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profile of TNM001 injection in healthy preterm and term infants.
- Trial name
- NCT05630573
- Testing
- TNM001
- Where
- 6 sites in China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
HIV Infections
An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects
To characterize the pharmacokinetics of orally administered FLT (in a liquid formulation) after single doses in both the fed and fasting states; to assess the effect of food on the oral bioavailability of FLT
- Trial name
- NCT00002260
- Testing
- Alovudine
- Where
- United States
- Sponsor
- Lederle Laboratories
Respiratory Syncytial Virus Infections
Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of SYH2066 tablets in adult patients with RSV infection.
- Trial name
- NCT07881991
- Testing
- SYH2066
- Where
- China
- Volunteers
- 80 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
COVID-19 Pandemic
A Study of FB2001 for Inhalation in Healthy Chinese Adults
FB2001 is a novel inhalable preparation being developed for COVID-19 treatment. A Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics Profile of Single and…
- Trial name
- NCT05583812
- Testing
- FB2001 for inhalation
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older
Primary Objective: To demonstrate that QIV-HD induced an immune response (as assessed by hemagglutination inhibition [HAI] geometric mean titers [GMTs] and seroconversion rates) that was superior to responses induced by QIV-SD…
- Trial name
- NCT04498832
- Testing
- High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD), Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)
- Where
- 10 sites in Japan
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infection, Human Immunodeficiency Virus
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV.
- Trial name
- NCT00296504
- Testing
- fosamprenavir (GW433908), ritonavir
- Where
- 24 sites in United States, Brazil and 6 more
- Volunteers
- 753 people
- Sponsor
- ViiV Healthcare